Jerini Announces Collaboration Agreement with Baxter to Develop Novel Peptide for Use in Therapeutic Protein Purification
BERLIN, Germany, Jan. 10, 2008 - Jerini AG (FSE:JI4) announced today the signing of a research collaboration agreement with Baxter AG to develop a novel synthetic molecule for use in affinity purification of a therapeutic protein. Under the terms of the agreement, Jerini will use its Peptides-to-Drugs (P2D) technology platform to identify and develop a specific binding molecule for protein purification, which potentially offers key advantages over conventional antibody-assisted protein purification.
"We are very pleased to announce our fourth collaboration agreement with Baxter. Jerini's proprietary P2D technology platform offers a unique and highly effective approach in the development of novel peptidomimetics or small molecules with applications in protein purification as well as drug development," said Jens Schneider-Mergener, Chief Executive Officer at Jerini.
Under the terms of the agreement, Jerini will receive an upfront payment and full time equivalents (FTE) funding along with potential milestone payments for the achievement of discovery, preclinical, and clinical goals and royalties on eventual product sales.
About Jerini AG Jerini is a pharmaceutical company based in
Berlin, Germany, focusing on the discovery, development, and
commercialization of novel peptide-based drugs. The company pursues
disease indications that have limited or no treatment options and
has built a drug pipeline composed of its own programs, as well as
others in collaboration with established partners. Jerini has filed
marketing approval applications for its lead product, Firazyr®
(Icatibant), in the treatment of hereditary angioedema, with both
the European Medicines Evaluation Agency and the US Food and Drug
Administration and expects regulatory decisions in the first half
of 2008. Based on its technology platform, Jerini has also
established several in-house development programs, which address
indications within the therapeutic areas of ophthalmology,
oncology, and inflammatory disease. ISIN: DE0006787476
For questions, please contact: Stacy Wiedenmann Director Investor Relations & Corporate Communications Jerini AG Invalidenstr. 130 10115 Berlin T + 49 - 30 - 97893 - 285 X + 49 - 30 - 97893 - 105 firstname.lastname@example.org
Posted: January 2008